Beam Therapeutics Inc.
BEAM-302
alpha-1 antitrypsin deficiency
Resolved
98days ago
Phase 2 readout · ~ Mar 31, 2026 estimated
What's at stake
Phase 2 trial results for BEAM-302 in alpha-1 antitrypsin deficiency are due ~ Mar 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Beam expects to report updated data from the Phase 1/2 trial and next steps for pivotal development by the end of the first quarter of 2026.”